TFX vs. DXCM, STE, PODD, HOLX, BAX, GMED, MASI, ITGR, IART, and ATRC
Should you be buying Teleflex stock or one of its competitors? The main competitors of Teleflex include DexCom (DXCM), STERIS (STE), Insulet (PODD), Hologic (HOLX), Baxter International (BAX), Globus Medical (GMED), Masimo (MASI), Integer (ITGR), Integra LifeSciences (IART), and AtriCure (ATRC). These companies are all part of the "health care equipment" industry.
Teleflex vs.
Teleflex (NYSE:TFX) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.
95.6% of Teleflex shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.4% of Teleflex shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, DexCom had 27 more articles in the media than Teleflex. MarketBeat recorded 33 mentions for DexCom and 6 mentions for Teleflex. DexCom's average media sentiment score of 0.88 beat Teleflex's score of 0.14 indicating that DexCom is being referred to more favorably in the news media.
Teleflex has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.
DexCom has higher revenue and earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
DexCom has a net margin of 17.22% compared to Teleflex's net margin of 7.85%. DexCom's return on equity of 31.40% beat Teleflex's return on equity.
Teleflex currently has a consensus target price of $252.50, suggesting a potential upside of 39.07%. DexCom has a consensus target price of $99.29, suggesting a potential upside of 17.67%. Given Teleflex's higher possible upside, equities analysts plainly believe Teleflex is more favorable than DexCom.
DexCom received 451 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 71.76% of users gave DexCom an outperform vote while only 59.19% of users gave Teleflex an outperform vote.
Summary
DexCom beats Teleflex on 15 of the 19 factors compared between the two stocks.
Get Teleflex News Delivered to You Automatically
Sign up to receive the latest news and ratings for TFX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teleflex Competitors List
Related Companies and Tools
This page (NYSE:TFX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free TFX Stock Alerts